QTORIN rapamycin 3.9 percent gel

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Topical mTOR inhibitors

7 evidence topics · 16 sources

French national diagnosis and care protocol: topical sirolimus

“Topical sirolimus is under clinical evaluation for these superficial cutaneous and mucosal LMs (NCT03972592, NCT04128722).” (opens the source at this quote in a new tab)

Medical therapies for pediatric lymphatic malformations: systematic review

“ultimately included 77 studies.” (opens the source at this quote in a new tab)
“Reported success rates were variable” (opens the source at this quote in a new tab)
“sirolimus (topical) (n = 13/15)” (opens the source at this quote in a new tab)

Other topical sirolimus formulations: 0.2% gel in pediatric superficial microcystic lymphatic malformations, case series

“0.2% topical sirolimus gel twice daily” (opens the source at this quote in a new tab)

Other topical sirolimus formulations: upper limb superficial lymphatic malformation case report

“a noticeable reduction in lesion size and bleeding was observed” (opens the source at this quote in a new tab)

Other topical sirolimus formulations: 1% rapamycin ointment case report

“1% rapamycin ointment” (opens the source at this quote in a new tab)

Other topical sirolimus formulations: microcystic lymphatic malformation case report with local irritation

“a local irritation occurred and the dose was decreased to once daily.” (opens the source at this quote in a new tab)

Other topical sirolimus formulations: efficacy and absorption in children with vascular anomalies

“topical sirolimus 0.1%” (opens the source at this quote in a new tab)